Table 4.
SurvExpress-based overall survival of 35 CCA patients.
| Immune Modulatory Gene | Risk Groups Hazard Ratio | Confidence Interval | Log-Rank Equal Curves (p-Value) |
|---|---|---|---|
| FASLG | 1.27 | 0.17–9.69 | 0.817 |
| LAG3 | 0.84 | 0.32–2.18 | 0.720 |
| HAVCR2 | 1.87 | 0.71–14.96 | 0.198 |
| VSIR | 1.69 | 0.61–4.68 | 0.309 |
| VTCN1 | 0.87 | 0.33–2.27 | 0.776 |
| TNFRSF9 | 81853258 | 0–∞ | 0.132 |
| TNFRSF14 | 1.39 | 0.53–3.66 | 0.503 |
| TIGIT | 1.37 | 0.5–3.71 | 0.536 |
| CD276 | 0.67 | 0.26–1.75 | 0.414 |
| CD27 | 1.15 | 0.42–3.11 | 0.785 |
| PDCD1LG2 | 1.53 | 0.55–4.21 | 0.409 |
| NT5E | 0.56 | 0.21–1.5 | 0.247 |
| CD80 | 3.41 | 0.45–25.04 | 0.208 |
| TNFRSF18 | 1.92 | 0.73–5.08 | 0.178 |
| BTLA | 1.36 | 0.31–5.97 | 0.686 |
| CD28 | 2.3 | 0.8–6.64 | 0.112 |